Source link : https://newshealth.biz/health-news/sacituzumab-or-chemo-in-first-line-tnbc-which-is-better/
Treatment with pembrolizumab and the antibody-drug conjugate (ADC) sacituzumab govitecan improved progression-free survival (PFS) in patients with PD-L1-positive locally advanced or metastatic triple-negative breast cancer (TNBC) compared with treatment with pembrolizumab and chemotherapy, the results of ASCENT-04/KEYNOTE-D19 showed. Swapping in sacituzumab govitecan for chemotherapy led to a 3.4-month improvement in PFS and an almost twofold […]
The post Sacituzumab or Chemo in First-Line TNBC: Which Is Better? first appeared on News Health.
—-
Author : News Health
Publish date : 2025-05-31 14:40:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8